Apolipoprotein E2 Genotype Is Associated with a 2-Fold Increase in the Incidence of Type 2 Diabetes Mellitus: Results from a Long-Term Observational Study

Table 3

Baseline prior history and medication of the 436 patients with different APOE alleles.

	APOE2 carriers	APOE3 homozygotes	APOE4 carriers	p value
	(N=51)	(N=283)	(N=102)
Prior history
HTA – no. (%)	27 (52.9)	139 (49.1)	39 (38.2)	0.11
T2DM – no. (%)	6 (11.8)	25 (8.8)	8 (7.8)	0.72
Current smokers – no. (%)	10 (25.0)	49 (22.2)	12 (15.0)	0.32
Alcohol consumption – no. (%)	13 (25.5)	65 (23)	12 (11.8)	0.37
Prior medication
Aspirin– no. (%)	17 (33.3)	85 (30.0)	23 (22.5)	0.26
Beta-blockers– no. (%)	7 (13.7)	45 (15.9)	11 (10.8)	0.45
ACEi – no. (%)	12 (23.5)	75 (26.5)	17 (16.7)	0.14
ARB – no. (%)	7 (13.7)	38 (13.4)	14 (13.7)	0.99
Calcium antagonist – no. (%)	8 (15.7)	36 (12.7)	13 (12.7)	0.84
Statins – no. (%)	24 (47.1)	179 (63.3)	48 (47.1)	0.005
Ezetimibe – no. (%)	7 (13.7)	34 (12.0)	6 (5.9)	0.18
Fibrates – no. (%)	15 (29.4)	47 (16.6)	24 (23.5)	0.06
Niacin/omega-3 fatty acids – no. (%)	1 (2.0)	10 (3.5)	1 (1.0)	0.48

HTA: hypertension; T2DM: type 2 diabetes mellitus; ACE: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker.